SI-BONE (SIBN) posted a third-quarter loss of $0.08 per share, beating the -$0.13 consensus by 38.5% and improving 27.3% from the prior year's $0.11 loss. Revenue rose 14.5% to $55.7 million, a modest 0.7% beat. The bottom-line beat is the cleaner part of the report, and the central tension sits just below it. U.S. procedure volume accelerated to roughly 19.5%, up from about 15% in the second quarter. Revenue growth, however, was essentially unchanged from Q2's 15.2%, and revenue slipped sequentially from $56.0 million. SI-BONE is doing more cases but collecting less per case, and management chose to hold, not raise, its full-year revenue outlook.

The quality of the earnings improvement is real, though modest in absolute terms. Gross profit grew 13.7% while operating expenses rose 9.7%, narrowing the operating loss to $4.4 million from $5.4 million. Adjusted EBITDA reached $3.0 million versus $2.3 million a year ago and $2.8 million in Q2. Operating cash flow was $5.9 million in the quarter, and cash and investments edged up to $146.3 million. Investors should keep two caveats in mind. First, the EBITDA figure excludes $5.7 million of stock-based compensation, so GAAP profitability remains some distance away. Second, year-to-date free cash flow was still negative $4.6 million. Inventory climbed to $42.4 million from $33.9 million at year-end as the company builds trays and implants for new launches. General and administrative spending was flat, so most of the leverage came from below the sales line. Sales and marketing continues to absorb much of the growth.

The call explained the gap between volume and revenue. U.S. average selling price declined because of mix. More Granite cases used two implants, and interventional spine physicians drove growth in the lower-priced INTRA platform in ASCs and office settings. That mix shift also nudged gross margin down to 79.3%, from 79.5% in Q2 and 79.8% in Q1. Other leading indicators softened as well. Active physician growth eased to 16% (about 1,770 surgeons) from 19% in Q2, and territory productivity growth fell to 7% from 11% in Q1. On the positive side, management cut 2026 operating expense growth guidance for a second time, to 10.5% from 12%. The gross margin and positive adjusted EBITDA targets were reaffirmed.

The forward case rests on a cluster of catalysts arriving at once:

• **iFuse Granite Onyx.** The device cleared FDA review in September and entered alpha launch in October, ahead of earlier "late 2026" framing. Management says early demand is tracking ahead of Granite's launch. Combined Granite-plus-Onyx cases use about six implants, which would reverse the ASP drag.
• **Reimbursement.** New Granite DRGs worth up to about $50,000 more per qualifying inpatient procedure took effect October 1. An Onyx NTAP application has been filed, and a CMS rule on outpatient SI-joint payment is expected for January.
• **Market size.** Management now pegs its addressable market at about $5 billion.

Bears still have legitimate ammunition. The reaffirmed $231-$233 million guide implies Q4 growth above 20%, a steep step-up from the mid-teens pace of the past two quarters, and it depends on these catalysts converting quickly. Some surgeons may wait six to twelve months for Onyx data. Management also flagged gross margin pressure in 2027 from Onyx tray depreciation and a roughly 78% margin longer term.

The market setup is more complicated than the surprise implies. Shares closed at $21.23 before the report, up 19.8% from the open following the August release and 29.4% above the 200-day moving average. They had set a 52-week high of $22.95 on October 29, just days before earnings, and finished the period about 7.5% below that peak. Investor sentiment moved the other way. It fell from -0.27 to -0.70, a substantial deterioration into an already negative reading. Price and sentiment are therefore pulling in opposite directions. The stock rallied on anticipation of the Onyx and DRG catalysts, even as the investor base grew notably more skeptical. The Earnings Whispers trend signals were largely positive heading into the print, with sequential growth the neutral exception, consistent with the flat revenue trajectory.

The bottom line is that SI-BONE delivered a solid earnings beat, accelerating procedure volume, and tighter cost discipline. Those gains were offset by flat revenue growth, slipping ASP and gross margin, and slowing physician additions. With guidance held rather than raised and the stock trading near its highs, the burden of proof now falls on the fourth quarter. Onyx uptake and the new DRGs need to turn volume gains into the 20%-plus revenue growth management's outlook requires.